Go online to PeerView.com/WEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you aware of the evidence supporting the use of innovative EHL FVIII therapies for the prophylactic management of hemophilia A? Find out in this activity based on a “MasterClass” event recorded at the 2023 Congress of the International Society on Thrombosis and Haemostasis. Hear what hemophilia experts are saying about the latest clinical evidence that supports the use of innovative EHL FVIII therapy in hemophilia as they link the data directly to case-based decisions in real-world settings—with a goal of clearly illustrating the practicalities of safely using novel and emerging factor products. The experts also provide guidance on implementing evidence-based protocols and preventing and managing complications in the context of EHL FVIII therapy. Upon completion of this activity, participants should be better able to: Assess the latest safety, efficacy, and pharmacokinetic data among currently approved and emerging EHL FVIII products for prophylaxis of hemophilia A; Develop personalized prophylactic regimens with novel and emerging EHL FVIII products based on patient- and disease-specific factors; and Manage practical aspects of care, such as patient education, adherence counseling, monitoring, and AE management, when using novel and emerging EHL FVIII products for prophylaxis of hemophilia A